acute myocardial infarction
Conditions
Interventions
Experimental group:Oral dapagliptin for 180 days
Control group:Oral placebo for 180 days
Sponsors
Tianjin Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Male or female hospitalized patients, aged 18 to 80 years; 2.Patients with acute ST-segment elevation myocardial infarction (STEMI) with successful direct PCI within 12 hours of onset; 3.Dual antiplatelet therapy with aspirin (ASA) and ticagrelor (DAPT) was used; 4.Into group 1 month before a diagnosis of type 2 diabetes, and has set up a hypoglycemic therapy, but not using glucagon like peptide agonist (glp-1 ra, such as the peptide), TZDS drugs (TZD use, such as pioglitazone) and sodium/glucose transporters - 2 inhibitor (SGLT - 2 I, such as net of Glenn) treatment in patients with type 2 diabetes; 5.Medically stable condition; 6.Voluntarily participate and sign informed consent.
Exclusion criteria
Exclusion criteria: 1.Type-1 diabetes; 2.Contraindication to MRI ; 3.Severe renal insufficiency (eGFR180mmHg or diastolic blood pressure >110mmHg (based on the blood pressure standard of admission visit); 7.Hypersensitivity to dapagliflozin or any excipients; 8.Patients with severe hepatic impairment (Child-Pugh class C); 9.Patients with active hepatitis B or C infection; 10.Patients with acute decompensated heart failure or hospitalized with decompensated heart failure within 4 weeks prior to enrollment; 11.Active bladder cancer or history of any other malignant tumor within 5 years (except for cured); 12.Diagnosis or history: (1)Acute metabolic diabetic complications such as ketoacidosis or hyperglycemic hyperosmolar state within 3 months; (2)Diabetes insipidus. 13.Participation in another clinical study; 14.Chronic cystitis and/or recurrent urinary tract infection (3 or more times in the past one year); 15.Screening of women of childbearing age and positive results of randomised pregnancy tests (i.e., women who have not received any medical or surgical contraception or who have not gone through menopause), or who have refused to use a medically acceptable method of contraception from the time of signing the informed consent until two weeks after the last use of medication, or women who are breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infarct area as a percentage of left ventricular size; | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular end diastolic dimension;Left ventricular mass index;Left ventricular ejection fraction;Amino-terminal pre-B-type natriuretic peptide; | — |
Countries
China
Contacts
Public ContactQin Qin
Chinese PLA General Hospital
Outcome results
None listed